Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeloda, Taxol and Herceptin in Metastatic Breast Cancer
NCT00006108Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Aug 1999
- Primary completion
- Sep 2001
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in breast cancer, sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoints: Maximum Tolerated Dose, Objective Response Rate and 3 more. Started Aug 1999; status: completed.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00006108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006108.